A multimodality approach to SGTs with PNI provides excellent LRC. Further studies are warranted to identify the patients at higher risk of LRF and DMs to optimize their management.
Bryan M. Rabatic, PhD, MD, David Zaenger, MD, Joseph M. Kaminski, MD, Waleed F. Mourad, MD, PhD; Georgia Regents University
PURPOSE: To report the clinical outcomes and patterns of failure of salivary gland tumors (SGTs) with perineural invasion (PNI) status postmultimodality approach (ie, surgery, postoperative radiation therapy [RT], and chemotherapy).
MATERIALS: This is a single-institution retrospective study that was fully approved by our institutional review board (IRB). From March 1997–2010, a total of 62 patients with SGTs underwent the multimodality approach due to the presence of PNI ± other high-risk features (recurrent tumor, R1 or R2 resection, positive margins, multiple positive lymph nodes, and extracapsular extension). Intensity-modulated RT (IMRT) was utilized in 50% of the patients. RT fields included the tumor bed, ipsilateral neck, and occasionally the contralateral neck. The most common pathologically involved nerves (facial, V2, and V3) were included in the RT fields to the skull base. The median RT dose delivered was 63 Gy (range: 50–70 Gy at 1.8–2 Gy/fraction). A total of 53%, 34%, and 13% of cases were parotid, minor salivary, and submandibular gland primaries, respectively. Pathologically adenoid cystic carcinoma and adenocarcinoma were the most common histologies (39% and 24%, respectively).
RESULTS: The median age was 53 years (range: 20–78 yr). Males and Caucasians made up 50% and 50% of the population, respectively. With a median follow-up of 5 years (range: 1–10 yr), the 5-year actuarial disease-free survival (DFS), locoregional control (LRC), and distant control (DC) rates were 85%, 94%, and 91%, respectively. The median time to LR failure (LRF) and distant metastases (DMs) was 8 months (range: 6–16 mo) and 30 months (range: 18–60 mo), respectively. Late RT toxicity was grade ≤ 2 xerostomia (20%), altered taste (15%), trismus (6%), dysphagia (4%), and neck stiffness (2%).
CONCLUSIONS: A multimodality approach to SGTs with PNI provides excellent LRC. Further studies are warranted to identify the patients at higher risk of LRF and DMs to optimize their management.
Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.